Transitioning your patients from Flolan® (epoprostenol sodium)1
Transitioning from Flolan to SC Remodulin1,2
Subcutaneous Remodulin has been demonstrated to diminish the rate of clinical deterioration* in patients requiring transition from Flolan.
- An 8-week, multicenter, randomized (2:1), placebo-controlled, withdrawal trial of 22 patients stable on epoprostenol therapy who were started on SC Remodulin or placebo
- Time to clinical deterioration* was the primary endpoint of this trial
- Safety findings were consistent with previous clinical trials of SC Remodulin
*Clinical deterioration was defined as an increase in Flolan dose, hospitalization due to PAH, or death (no patients died during this study).1
Figure adapted with permission from Rubenfire M, et al. Chest. 2007.
93% of patients (13 of 14) successfully transitioned from epoprostenol IV to SC Remodulin1,2
Transitioning from Flolan to IV Remodulin3
- In a 12-week, multicenter, open-label, investigator-initiated trial, 31 patients receiving optimal doses of conventional IV PAH therapies, as well as a stable dose of Flolan for ≥1 month were transitioned to IV Remodulin
- 6MWD was maintained in patients changing from Flolan to IV Remodulin (438 m vs 439 m, respectively)
- Borg dyspnea scores: no significant change
Transition from Flolan protocol
Transition from Flolan to Remodulin is accomplished by initiating and increasing the infusion of Remodulin (at a recommended dose of 10% of the current Flolan dose). The Remodulin dose should be increased as the Flolan dose is simultaneously decreased.1
Monitor your patients in a hospital to measure their response to Remodulin, including observing their vital signs, potential adverse reactions, and disease progression symptoms.1
6MWD=6-minute walk distance; IV=intravenous; PAH=pulmonary arterial hypertension; SC=subcutaneous.